Asset
RETIFANLIMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03522142 | phase1 | terminated | 2018-08-27 | 2025-09-10 | Incyte Corporation | A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies |
| NCT04580485 | phase1 | completed | 2021-02-03 | 2024-01-22 | Incyte Corporation | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.